Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vote In favor of Your Number one Game Control center - 2Senegal president signs tough new anti-LGBT law doubling jail terms
- 3Vote In favor of Your Favored Web-based Book Retailor
- 4Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026
- 5A Colombian city swaps iconic horse buggies for electric carriages amid animal welfare concerns
- Artemis II live updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
- Starbucks' new 'Bearista' cup is causing a stir — and is being listed on eBay for $600
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Kids
- Paraplegic engineer becomes the first wheelchair user to blast into space
- Ancient Egyptian pharaoh's boat is being reassembled in public at the Grand Egyptian Museum
- Authorities Bust Camel Booze Smuggling Operation, Seize Nearly 2,000 Containers of Illegal Alcohol
- Vote in favor of Your Number one kind of pie
- Poll: Only 25% of Americans think Trump has 'followed through' on his promise to release the Epstein files
- Dominating Monetary Administration: A Bit by bit Manual for Making an Individual Financial plan
